期刊
INTERNATIONAL IMMUNOPHARMACOLOGY
卷 107, 期 -, 页码 -出版社
ELSEVIER
DOI: 10.1016/j.intimp.2022.108655
关键词
COVID-19; SARS-CoV-2; Immune cell therapy; Treg therapy; NK therapy; MSC therapy; DC therapy; CAR -T cell therapy; Viral specific T cell therapy
Efforts are being made to control and treat COVID-19 worldwide. Adoptive immune cell therapy is an innovative approach that offers promising prophylactic or therapeutic options, but it may result in excessive inflammation.
Multiple efforts are currently underway to control and treat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), causing coronavirus disease 2019 (COVID-19) worldwide. Despite all efforts, the virus that emerged in Wuhan city has rapidly spread globally and led to a public health emergency of international concern (PHEIC) due to the lack of approved antiviral therapy. Nevertheless, SARS-CoV-2 has had a significant influence on the evolution of cellular therapeutic approaches. Adoptive immune cell therapy is innovative and offers either promising prophylactic or therapy for patients with moderate-to-severe COVID-19. This approach is aimed at developing safety and providing secure and effective therapy in combination with standard therapy for all COVID-19 infected individuals. Based on the effective results of previous studies on both inflammatory and autoimmune diseases, various immune cell therapies against COVID-19 have been reviewed and discussed. It must be considered that the application of cell therapy for treatment and to eliminate infected respiratory cells could result in excessive inflammation, so this treatment must be used in combination with other treatments, despite its many beneficial efforts.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据